Phillip Frost, CEO and Chairman of OPKO Health, Inc. (NASDAQ:OPK), has increased his holdings in the company. According to a recent SEC filing, Frost acquired 100,000 shares of OPKO Health common stock on November 22, 2024. The shares were purchased at a weighted average price of $1.59 per share, amounting to a total transaction value of $159,000.
This acquisition was made through Frost Gamma Investments Trust, where Frost serves as trustee. Following this transaction, Frost's indirect ownership in OPKO Health totals 211,712,405 shares. Additionally, he holds direct ownership of 3,568,951 shares and indirect ownership of 30,127,177 shares through other entities.
These transactions highlight Frost's continued investment in OPKO Health, reinforcing his significant stake in the company.
In other recent news, OPKO Health has reported a mixed performance for its Q3 2024 results. Despite experiencing a decrease in quarterly revenue to $121.3 million from $131.7 million in Q3 2023, the company managed to turn around to a net income of $24.9 million compared to the previous year's net loss. The company's balance sheet remains solid, with over $400 million in cash.
Significant developments include the sale of BioReference Health's clinical diagnostics assets for $237.5 million and a 16% growth in the company's 4K score test for prostate cancer. OPKO's collaboration with Merck (NS:PROR) on an Epstein-Barr virus vaccine could result in milestone payments of up to $872.5 million, and their partnership with Pfizer (NYSE:PFE) on NGENLA is gaining market traction.
Furthermore, the company has repurchased 24 million shares for $37.3 million under its share buyback program. The company's future revenue projections for Q4 2024 are between $155 million and $160 million, with operational profitability expected by year-end. These are among the recent developments at OPKO Health.
InvestingPro Insights
Phillip Frost's recent acquisition of OPKO Health shares aligns with one of the key InvestingPro Tips for the company: "Management has been aggressively buying back shares." This insider buying activity often signals management's confidence in the company's future prospects.
Despite the recent purchase, OPKO Health faces some challenges. According to InvestingPro Data, the company's revenue for the last twelve months as of Q3 2023 stood at $711.41 million, with a concerning revenue growth of -17.94% over the same period. This decline is consistent with another InvestingPro Tip that states "Analysts anticipate sales decline in the current year."
However, it's not all gloomy for OPKO Health. An InvestingPro Tip suggests that "Net income is expected to grow this year," which could explain Frost's continued investment in the company. Additionally, with a Price to Book ratio of 0.77, the stock might be considered undervalued by some investors.
For those interested in a deeper analysis, InvestingPro offers 7 additional tips for OPKO Health, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.